Search companies or stocks...
On the Key Ratios page for XTL Biopharmaceuticals Ltd. (XTLB), the latest P/E of -0.8 frames valuation, while ROE -269.02% and ROIC -11253.33% indicates profitability and capital efficiency. Together with the current ratio of 0.40 and debt-to-equity -1.06, these signals help you judge whether valuation is supported by fundamentals across the historical rows.
| Metric (FY) | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income per Share | $-0.78 | $-0.00 | $-0.00 | $-0.00 | $0.00 | $-0.00 | $-0.00 | $0.01 | $-0.00 | $-0.01 |
| Operating Cash Flow per Share | $-0.11 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.01 |
| Free Cash Flow per Share | $-0.11 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.01 |
| Cash per Share | $0.02 | $0.00 | $0.00 | $0.01 | $0.01 | $0.01 | $0.01 | $0.02 | $0.01 | $0.01 |
| Book Value per Share | $-0.03 | $0.01 | $0.00 | $0.01 | $0.01 | $0.01 | $0.01 | $0.02 | $0.01 | $0.01 |
| Tangible Book Value per Share | $-0.03 | $-0.00 | $0.00 | $0.01 | $0.01 | $0.01 | $0.01 | $0.02 | $0.01 | $0.01 |
| Interest Debt per Share | $0.03 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| CAPEX per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Metric (FY) | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to Earnings (P/E) | -0.78 | -11.69 | -2860.68 | -0.05 | 0.39 | -0.2 | -0.05 | 0.03 | -0.15 | -0.03 |
| Price to Book (P/B) | -22.15 | 2.21 | 2.3 | 0.02 | 0.03 | 0.04 | 0.01 | 0.01 | 0.03 | 0.03 |
| Price to Sales (P/S) | 0 | 26.62 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Enterprise Value to EBITDA | -4.85 | -12.66 | -4.84 | 2.31 | 2.72 | 3.67 | 0 | 4 | 2.55 | 1.13 |
| EV to Sales | 0 | 26.11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV to Operating Cash Flow | -5.98 | -7.28 | -5.23 | 2.25 | 2.67 | 4.09 | 4.83 | 3.88 | 2.82 | 1.12 |
| EV to Free Cash Flow | -5.98 | -7.04 | -5.23 | 2.25 | 2.67 | 4.08 | 4.82 | 3.88 | 2.82 | 1.08 |
| Enterprise Value | $6.13M | $11.77M | $3.70M | $-2.03M | $-2.80M | $-3.47M | $-4.39M | $-3.17M | $-3.17M | $-1.94M |
| Metric (FY) | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -269.02% | -18.90% | -0.08% | -33.71% | 8.16% | -21.65% | -19.30% | 35.88% | -21.58% | -94.72% |
| Return on Invested Capital (ROIC) | -11253.33% | -29.75% | -34.46% | -22.01% | -16.14% | -15.17% | -11.45% | -9.78% | -19.82% | -95.31% |
| Return on Tangible Assets | -4198.19% | -66.65% | -0.09% | -35.42% | 6.97% | -12.77% | -19.72% | 36.44% | -12.58% | -92.08% |
| Earnings Yield | -123.86% | -8.55% | -0.03% | -2024.52% | 255.34% | -498.95% | -1928.30% | 3396.65% | -671.69% | -3039.01% |
| Free Cash Flow Yield | -17.25% | -13.93% | -13.87% | -1353.18% | -615.75% | -542.97% | -1302.71% | -928.22% | -967.54% | -2147.01% |
| Dividend Yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Metric (FY) | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.61 | 9.93 | 20.35 | 27 | 24.1 | 29.44 | 32.39 | 20.69 | 8.35 |
| Interest Coverage | -241.14 | -77.57 | 0 | 0 | 0 | 0 | -29.03 | 0 | 0 | 0 |
| Income Quality | 0.15 | 1.58 | 0.4 | 0.67 | -2.41 | 1.09 | 0.67 | -0.27 | 1.44 | 0.68 |
| Debt to Equity | -1.06 | 0.03 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt to Assets | 162.05% | 1.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Debt to EBITDA | -0.15 | 0.25 | 1.83 | 2.38 | 2.88 | 3.83 | 0 | 4.11 | 2.64 | 1.18 |
| Metric (FY) | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Receivables Turnover | 0 | 4.56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Payables Turnover | 0 | 2.29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory Turnover | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 0 | 80.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | 0 | 159.69 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days of Inventory on Hand | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric (FY) | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Enterprise Value to EBITDA | -4.85 | -12.66 | -4.84 | 2.31 | 2.72 | 3.67 | 0 | 4 | 2.55 | 1.13 |
| Market Cap | $5.94M | $12.01M | $5.10M | $66,583.77 | $170,362.39 | $156,729.72 | $69,854.24 | $87,910.27 | $116,274.36 | $83,744.27 |
| Enterprise Value | $6.13M | $11.77M | $3.70M | $-2.03M | $-2.80M | $-3.47M | $-4.39M | $-3.17M | $-3.17M | $-1.94M |
| Dividend Yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Payout Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On this page, XTLB's current P/E is -0.8, compared with a multi-year average around 0.2. A lower P/E versus its own history is a calculated gap versus that average—not a conclusion that the stock is cheap. Pair it with profitability and earnings quality in the table (for example ROE/ROIC) to see whether the multiple moved with earnings.
Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $5.94M. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.
There is no P/E Tickerplace rates as good. Compare the P/E on this page with XTL Biopharmaceuticals Ltd.'s own historical range (in the table) and with peers via the Screener and Compare tools. A higher or lower multiple versus peers is a calculated gap, not a recommendation.
The fastest way to compare XTL Biopharmaceuticals Ltd. with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see XTL Biopharmaceuticals Ltd. outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.
Liquidity and leverage figures on this page are published ratios, not a verdict that XTL Biopharmaceuticals Ltd. is financially strong. Current ratio is about 0.40, which is below 1.0 and can suggest tighter short-term liquidity. Interest coverage is about -241.14, implying less buffer for servicing interest costs. Debt-to-equity is about -1.06, suggesting leverage is more moderate relative to a high-debt profile. Pair them with ROE/ROIC and cash-flow rows in the table. Tickerplace does not rate the company as a good or poor investment.
Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If XTL Biopharmaceuticals Ltd. is sustaining strong returns (for example ROE at -269.02% and ROIC at -11253.33%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.
